- Ocugen (OCGN, Financial) to host a conference call on May 9, 2025, at 8:30 a.m. ET.
- The call will discuss Q1 2025 financial results and business updates.
- Earnings announcement to be released before market opens on May 9.
Ocugen, Inc. (OCGN), a leading biotechnology company specializing in gene therapies for blindness diseases, has announced plans to host a conference call and live webcast on Friday, May 9, 2025, at 8:30 a.m. ET. The event will cover the company's financial results for the first quarter of 2025 and provide business updates.
The company's earnings announcement will be released before the market opens on May 9. Interested investors can join the conference call via phone by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for international callers, using Conference ID 1773288. Additionally, a live webcast of the call will be available on the Ocugen investor site, and a replay of the call will be accessible for approximately 45 days following the event.
As a pioneering biotechnology firm, Ocugen continues to develop gene therapies aimed at addressing blindness diseases, with a focus on inherited retinal disorders and conditions such as retinitis pigmentosa, Stargardt disease, and geographic atrophy. Through its innovative modifier gene therapy platform, Ocugen aims to address significant unmet medical needs in large patient populations globally.
